Table 2 baseline characteristics of the included studies
Study ID | study groups | age (years) mean(SD) | BMI Mean ( SD) | Basal AMH (ng/ml) Mean ( SD) | Basal LH (IU/l) Mean ( SD) | Basal FSH (IU/ml) Mean ( SD) | Duration of infertility in years Mean ( SD) | Primary infertility Number, percentage | Secondary infertility Number, percentage |
|---|---|---|---|---|---|---|---|---|---|
Eftekhar et al. 2018 [29] | PRP | 31.98 (2.26) | NR | NR | NR | NR | NR | 29, 72.5% | 11, 27.5% |
control | 32.4 (2.63) | NR | NR | NR | NR | NR | 31, 72.1% | 12, 27.9% | |
Nazari et al. 2019 [30] | PRP | 33.95 (2.76) | 24.3 (2.24) | NR | NR | NR | NR | NR | NR |
control | 32.33 (4.79) | 25.46 (2.68) | NR | NR | NR | NR | NR | NR | |
Nazari et al. 2020 [31] | PRP | 35.37 (3.49) | 25.61 (3.13) | NR | NR | NR | NR | NR | NR |
control | 34.95 (4.23) | 25.46 (2.68) | NR | NR | NR | NR | NR | NR | |
Allahveisi et al. 2020 [17] | PRP | 33 (0.9) | 25.96 (0.54) | 3.91 (0.7) | 4.78 (0.43) | 6.42 (0.49) | 2.68 (0.12) | 19,76% | 6, 25% |
control | 33.8 (0.54) | 25.76 (0.47) | 6.87 (1.4) | 6.01 (1.1) | 6.16 (0.6) | 2.9 (0.14) | 19, 76% | 6, 25% | |
Rageh et al. 2020 [33] | PRP | 29.3(3.5) | 26.7 (1.1) | 1.81 (0.96) | NR | NR | 6.6 (3.7) | NR | NR |
control | 29.9 (3.9) | 26.6 (1.08) | 1.577 (0.84) | NR | NR | 6.2 (4.4) | NR | NR | |
Zamaniyan et al. 2021 [20] | PRP | 33.88 (6.32) | 26.49 (4.53) | NR | NR | NR | 6.12 (4.51) | 34, 61.8% | 18,32.7% |
control | 33.13 (5) | 25.03 (3.66) | NR | NR | NR | 6.17 (3.5) | 36, 83.7% | 11.60% | |
Zargar et al. 2021 [35] | PRP | 34.15 (5.14) | NR | NR | NR | NR | 7.5 (4.73) | 34,85% | 6,15% |
control | 32.82 (5.18) | NR | NR | NR | NR | 6.95 (3.04) | 32, 80% | 8, 20% | |
Ershadi et al. 2022 [16] | PRP | 31.3 (4.3) | 26.5 (3.2) | NR | NR | NR | NR | NR | NR |
control | 31.2 (4.8) | 27.7 (3) | NR | NR | NR | NR | NR | NR | |
Safdarian et al. 2022 [34] | PRP | 33.4 (4.9) | 24.85 (2.84) | 2.51 (1.22) | NR | NR | NR | NR | NR |
control | 34 (3.73) | 25.24 (2.71) | 2.64 (2.99) | NR | NR | NR | NR | NR | |
Nazari et al. 2022 a [15] | PRP | 34.11 (3.75) | 24.73 (3.53) | 4.15 (2.23) | 4.14 (0.3) | 0.0064 (0.0032) | 4.3 (2.3) | 155,79.1% | 41, 20.9% |
control | 33.61 (4.06) | 25.19 (3.01) | 3.94 (2.75) | 3.87 (0.8) | 0.0067 (0.0012) | 4.6 (1.4) | 160, 81.2% | 37, 18.8% | |
Nazari et al. 2022 b [32] | PRP | 35.7 (5.1) | 26.4 (3.43) | 2.93 (1.91) | NR | 5.11 (2.68) | 5.2 (3.6) | 10, 50% | 10, 50% |
control | 34.75 (4.57) | 26.6 (4.23) | 2.1 (1.67) | NR | 4.28 (2.92) | 3.65 (2.15) | 5,25% | 15, 75% | |
Dzhincharadze et al. 2021 [28] | PRP | 36 (6) | 23.13 (3.35) | NR | 5.1 (3.5) | 0.0079 (0.0063) | 5.22 (3.8) | NR | NR |
control | 36.8 (6.8) | 23.66 (3.5) | NR | 4.53 (2.95) | 0.00842 (0.00799) | 6.74 (5.65) | NR | NR | |
Tehraninejad et al. 2021 [18] | PRP | 32.9 (3) | 26.2 (2.8) | 2.4 (3.7) | NR | 0.0064 (0.0022) | 8.9 (6.2) | NR | NR |
control | 33.5 (2.5) | 26.3 (3.3) | 2 (2.7) | NR | 0.0063 (0.0024) | 11 (7) | NR | NR | |
Abou-El-Naga et al. 2022 [26] | PRP | 31.9(2.5) | 27.2 (1.9) | NR | NR | NR | 4.6 (1.7) | 7,35% | 13,65% |
control | 26.4 (3.8) | 27.6 (2) | NR | NR | NR | 5.1 (1.3) | 7,35% | 13, 65% | |
chang et al. 2019 [27] | PRP | 34.77 (0.75) | 22.42 (0.42) | NR | 4.8 (1.19) | 0.00591 (0.00177) | 3.57 (1.82) | NR | NR |
control | 32.64 (1.7) | 22.39 (0.8) | NR | 4.31 (1.32) | 0.00636 (0.00184) | 3.71 (1.66) | NR | NR | |
Coksuer et al. 2019 [19] | PRP | 29.41 (4.54) | 26.35 (4.41) | NR | 7.2 (0.93) | 0.0073 (0.001225) | 7 (3) | NR | NR |
control | 28.89 (3.91) | 26.78 (3.79) | NR | 6.5 (0.38) | 0.0069 (0.00155) | 8 (2.75) | NR | NR | |
Noushin et al. 2021 [13] | PRP | 32.28 (4.84) | 26.28 (0.89) | 3.87 (3.03) | NR | NR | 5.99 (1.78) | NR | NR |
control | 33.01 (4.27) | 26.32 (0.93) | 4.14 (2.62) | NR | NR | 5.33 (1.77) | NR | NR | |
Xu et al. 2022 [14] | PRP | 34.92 (4.8) | 24.08 (3.65) | 3.38 (2.45) | NR | 6.69 (1.5) | 4.35 (3.29) | 75, 54% | 63, 46% |
control | 34.93 (4.87) | 24.81 (3.9) | 2.4 (3.03) | NR | 6.45 (1.47) | 4.28 (3.74) | 78, 52% | 72, 48% | |
Abduljabbar et al. 2022 [36] | PRP | 35.91 (4.49) | NR | NR | NR | NR | NR | 16, 45.7% | 19, 54% |
control | 34.63 (4.26) | NR | NR | NR | NR | NR | 14, 40% | 21, 60% | |
Baybordi et al. 2022 [38] | PRP | 37.33 (6.439) | 26.64 (3.302) | NR | NR | NR | 12 (6.16) | 36, 75% | 12, 25% |
control | 32.41 (5.651) | 26.86 (3.63) | NR | NR | NR | 7 (4.71) | 39, 85% | 7, 15% | |
Yuan et al. 2022 [40] | PRP | ≥ 35 year 19 < 35 year 11 | NR | NR | 5.78 (2.49) | 0.00845 (0.00204) | ≥ 4 year 17 < 4 year 13 | NR | NR |
control | ≥ 35 year 26 < 35 year 8 | NR | NR | 5.68 (2.01) | 0.00851 (0.00218) | ≥ 4 year 19 < 4 year 15 | NR | NR | |
Ban et al. 2023 [37] | PRP | 32.04 (4.36) | 20.69 (4.36) | 4.72 (3.84) | 6.32 (5.38) | 0.00664 (0.00321) | 3 (1.52) | NR | NR |
control | 32.22 (4.31) | 22.52 (2.99) | 4.82 (3.56) | 5.15 (2.7) | 0.00578 (0.00227) | 3.5 (2.28) | NR | NR | |
Pourkaveh et al. 2022 [39] | PRP | 35.18 (2.09) | 23.09 (1.3) | NR | NR | NR | 5.91 (0.94) | NR | NR |
control | 34.67 (2) | 23.11 (2.09) | NR | NR | NR | 6.11 (1.05) | NR | NR |